echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Kintor Pharmaceutical's AR-PROTAC (GT20029) Phase I clinical trial in China completed subject enrollment and administration

    Kintor Pharmaceutical's AR-PROTAC (GT20029) Phase I clinical trial in China completed subject enrollment and administration

    • Last Update: 2022-08-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    SUZHOU, Aug.


    This Phase I clinical trial in China is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of single and multiple topical administration of GT20029 (gel/tincture) in healthy subjects.


    Preclinical studies have shown that GT20029 can effectively block the AR signaling pathway and its physiological function by degrading AR protein.


    Dr.


    About GT20029

    GT20029 is a topical compound developed by Kintor Pharmaceuticals based on PROTAC technology.


    Source: Kintor Pharmaceuticals

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.